Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012
Research

High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009–2010

Elisabeth Sanchez-PadillaComments to Author , Themba Dlamini, Alexandra Ascorra, Sabine Rüsch-Gerdes, Zerihun Demissie Tefera, Philippe Calain, Roberto de la Tour, Frauke Jochims, Elvira Richter, and Maryline Bonnet
Author affiliations: Epicentre, Paris, France (E. Sanchez-Padilla, A. Ascorra, M. Bonnet); National Tuberculosis Control Programme, Mbabane, Swaziland (T. Dlamini); National Reference Center for Mycobacteria, Borstel, Germany (S. Rüsch-Gerdes, E. Richter); Médecins Sans Frontières, Geneva, Switzerland (Z.D. Tefera, P. Calain, R. de la Tour, F. Jochims)

Main Article

Table 2

Patterns of first-line drug resistance in new and previously treated case-patients with TB, Swaziland 2009–2010*

Resistance pattern New, n = 352
 Previously treated, n = 281
No. (%) 95% CI No. (%) 95% CI
Susceptible to all first-line drugs 298 (84.7) 80.9–88.4 142 (50.5) 44.7–56.4
Any resistance 54 (15.3) 11.6–19.1 139 (49.5) 43.6–55.3
Isoniazid 47 (13.4) 9.8–16.9 127 (45.2) 39.4–51.0
Rifampin 28 (8.0) 5.1–10.8 102 (36.3) 30.7–41.9
Ethambutol 29 (8.2) 5.4–11.1 94 (33.5) 27.9–39.0
Streptomycin 47 (13.4) 9.8–16.9 115 (40.9) 35.2–46.7
Monoresistance 12 (3.4) 1.5–5.3 24 (8.6) 5.3–11.8
Isoniazid 5 (1.4) 0.2–2.7 12 (4.3) 1.9–6.6
Rifampin 1 (0.3) 0.0–0.8 7 (2.5) 0.7–4.3
Ethambutol 0 0
Streptomycin 6 (1.7) 0.4–3.1 5 (1.8) 0.2–3.3
MDR 27 (7.7) 4.9–10.5 95 (33.8) 28.3–39.3
Isoniazid + rifampin 1 (0.3) 0.0–0.8 3 (1.1) 0.0–2.3
Isoniazid + rifampin + ethambutol 0 2 (0.7) 0.0–1.7
Isoniazid + rifampin + streptomycin 6 (1.7) 0.4–3.1 12 (4.3) 1.9–6.6
Isoniazid + rifampin + streptomycin + ethambutol 20 (5.7) 3.3–8.1 78 (27.8) 22.5–33.0
Other first-line drug-resistance patterns different from MDR 15 (4.3) 2.2–6.4 20 (7.1) 4.1–10.1
Isoniazid + streptomycin 6 (1.7) 0.4–3.1 6 (2.1) 0.4–3.8
Isoniazid + streptomycin + ethambutol 9 (2.6) 0.9–4.2 14 (5.0) 2.4–7.5

*New case-patients were those not previously treated for TB or who had taken anti-TB drugs in the past for <1 month. TB, tuberculosis; MDR, multidrug resistant.

Main Article

Page created: December 16, 2011
Page updated: December 16, 2011
Page reviewed: December 16, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external